# ArkeaBio

> ArkeaBio is a Boston climate-biotech company building the first vaccine that cuts methane emissions from cattle. The shot trains a cow's immune system to produce antibodies that travel to the rumen and suppress methanogens - the microbes that turn digestion into greenhouse gas. Livestock methane accounts for roughly 6% of global emissions, and ArkeaBio's pitch is blunt: a vaccine is the lowest-cost, most scalable way to attack that number. Backed by Breakthrough Energy Ventures and a roster of climate and ag investors, the company is moving from animal studies into full field trials, targeting a 20% methane reduction and a first product in market around 2028.

- **Founded:** 2022
- **Headquarters:** Boston, Massachusetts, United States
- **Founders:** Colin South (Founder & CEO)
- **Team size:** ~37 employees
- **Products:** Methane-reducing livestock vaccine
- **Notable:** First company to demonstrate methane reduction in cattle from a vaccine, Raised a $26.5M Series A led by Breakthrough Energy Ventures (May 2024), Total funding of roughly $45.5M as of 2025

## Products & services

- **Methane-reducing livestock vaccine** — A vaccine that prompts the animal's immune system to produce antibodies which travel into the rumen and bind to methanogens, impairing their fitness so methane-producing microbes are out-competed. Designed to be non-GMO, organic-compatible, safe for meat and milk, and to integrate with existing farm vaccination practices. Cost target under $100 per ton of CO2-equivalent reduced; methane-reduction target around 20% with effectiveness lasting six months or more.

## Achievements

- First company to demonstrate methane reduction in cattle from a vaccine
- Raised a $26.5M Series A led by Breakthrough Energy Ventures (May 2024)
- Total funding of roughly $45.5M as of 2025
- Cattle trials with Texas A&M University showing measurable methane reduction
- Repeated follow-on backing from AgriZeroNZ through 2025

## Latest updates

- **2025-09** — AgriZeroNZ invested a further ~$3.5M USD to support the company's path to commercialization for New Zealand farmers and expand animal trials into New Zealand, targeting a first product in market around 2028.
- **2025** — Appointed Dr. Zach Serber as Chief Technology Officer to speed development of the methane-reducing vaccine.
- **2025** — Reported progress toward a 20% methane-reduction target with effectiveness lasting six months or more, on track to move from animal studies into full field trials in 2026.

## Links

- Website: https://arkeabio.com
- LinkedIn: https://www.linkedin.com/company/arkeabio/
- Twitter/X: https://twitter.com/arkeabio
- Facebook: https://facebook.com/arkeabio

---

Profile page: https://yespress.io/arkeabio
Published by YesPress — https://yespress.io
Last updated: 2026-06-16